Author/Authors :
Borgers، نويسنده , , Heleen and Moens، نويسنده , , Leen and Picard، نويسنده , , Capucine and Jeurissen، نويسنده , , Axel and Raes، نويسنده , , Marc K. Sauer، نويسنده , , Kate and Proesmans، نويسنده , , Marijke and De Boeck، نويسنده , , Kris and Casanova، نويسنده , , Jean-Laurent and Meyts، نويسنده , , Isabelle and Bossuyt، نويسنده , , Xavier، نويسنده ,
Abstract :
We evaluated a multiplexed bead-based assay (xMAP® Pneumococcal Immunity assay from Luminex) for the simultaneous determination of antibodies against 14 capsular polysaccharides. Post-vaccination (Pneumovax®) antibody concentrations were measured in 35 healthy children, 40 healthy adults, 99 consecutive patients with increased susceptibility to respiratory infection, and 24 patients with a deficient anti-polysaccharide antibody response. The serotype-specific lower 5th percentile (cutoff) value for the post-immunization antibody concentration was determined in healthy individuals. Eleven of 99 patients (11%) failed to mount a response that was > 5th percentile of controls for at least 6 of the 14 serotypes tested, whereas only 3 of 75 controls (4%) failed to do so. All patients with known anti-polysaccharide antibody deficiency failed to mount a response that was > 5th percentile of controls for at least 6 of the 14 serotypes tested. The XMAP® pneumococcal immunity panel appears useful for identifying individuals with a low response to the unconjugated pneumococcal vaccine.